MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Read moreMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Read moreMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Read moreOncology Focused, Patient Centric
We are committed to the development of novel and differentiated cancer therapies intended to provide improved outcomes to patients
